All News
Humira Clobbers Biosimilars in Battle for Part D Coverage
Medpage Today
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.
Read Article
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
National Psoriasis Foundation’s 2019 Annual Survey of 1,570 #PSO pts found among 801 w/ PsA most (59.6%) report unacceptable levels of disease activity, which is associated with increased prevalence of depression and limitations in social participation. https://t.co/HtWcAhZ6Zu https://t.co/pdC4IjIxmj
Links:
Dr. John Cush RheumNow ( View Tweet)
Israeli study shows the prevalence of Psoriatic arthritis has tripled since 2006
- 2006: 0.073%
- 2016: 0.165%
- 2022: 0.221%
~2 fold higher rate if Jewish, High SES, Obese
https://t.co/RMWcIZvfjb https://t.co/9H6sauSEZK https://t.co/Fhj64pADdJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review on Psoriasis Flares; risks:
- mechanical stress
- infections
-dysbiosis
-drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN)
- environment(smoking, obesity)
-lifestyle
- stress
- hormonal/metabolic https://t.co/WfCzcG9XNM https://t.co/ZNeKxjtHSA https://t.co/sJDoSfFOL4
Dr. John Cush RheumNow ( View Tweet)
Study of 150 #PsA pts & Aortic stiffness (carotid-femoral pulse wave velocity (cfPWV) - cfPWV signif higher in PsA vs controls (p=0.034). , cfPWV assoc w/ Dz duration (r=0.3), systolic BP, GFR, RDW. cfPWV was superior to SCORE (16% vs 8.7%) at CV risk https://t.co/H6SbsIdXw0 https://t.co/Yt19QCk9TT
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow ( View Tweet)
Biomarkers Predictive of a Deucravacitinib Response in PsA
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses.
https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4
Dr. John Cush RheumNow ( View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/9t41cjROwW https://t.co/9AelBwoRzs
Dr. John Cush RheumNow ( View Tweet)
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs
Dr. John Cush RheumNow ( View Tweet)
